{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:19:04Z","timestamp":1781533144507,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1995,1,1]],"date-time":"1995-01-01T00:00:00Z","timestamp":788918400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother. Pharmacol."],"published-print":{"date-parts":[[1995]]},"DOI":"10.1007\/bf00688324","type":"journal-article","created":{"date-parts":[[2004,11,28]],"date-time":"2004-11-28T17:25:14Z","timestamp":1101662714000},"page":"247-253","source":"Crossref","is-referenced-by-count":86,"title":["Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation"],"prefix":"10.1007","volume":"37","author":[{"given":"Gilles","family":"Vassal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Koscielny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Challine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Valteau-Couanet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Boland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Deroussent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Lemerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Gouyette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1200\/JCO.1992.10.6.995","volume":"10","author":"LJ Ayash","year":"1992","unstructured":"Ayash LJ, Wright JE, Tretyakov O, Gonin R, Alias A, Wheeler C, Eder JP, Rosowsky A, Antman K, Frei E III (1992) Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 10: 995","journal-title":"J Clin Oncol"},{"key":"CR2","first-page":"53","volume":"3","author":"L Brugi\u00e8res","year":"1988","unstructured":"Brugi\u00e8res L, Hartmann O, Benhamou E, Zafrani ES, Caillaud JM, Patte C, Kalifa C, Flamant F, Lemerle J (1988) Veno-occlusive disease of the liver following high-dose chemotherapy and autologous bone marrow translantation in children with solid tumors: incidence, clinical course and outcome. Bone Marrow Transplant 3: 53","journal-title":"Bone Marrow Transplant"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/BF00256174","volume":"16","author":"A Gouyette","year":"1986","unstructured":"Gouyette A, Hartmann O, Pico J-L (1986) Pharmacokinetics of high-dose melphalan in children and adults. Cancer Chemother Pharmacol 16: 184","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR4","first-page":"18","volume":"20","author":"LB Grochow","year":"1993","unstructured":"Grochow LB (1993) Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 20: 18","journal-title":"Semin Oncol"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF00694339","volume":"25","author":"LB Grochow","year":"1989","unstructured":"Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen T-G, Saral R, Santos GW, Colvin OM (1989) Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 25:55","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V75.8.1723.1723","volume":"75","author":"B Grochow","year":"1990","unstructured":"Grochow B, Krivit W, Whitley LB, Blazar B (1990) Busulfan disposition in children. Blood 75: 1","journal-title":"Blood"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/BF00558081","volume":"36","author":"M Hassan","year":"1989","unstructured":"Hassan M, Oberg G, Ehrsson H, Ehrnebo M, Wallin I, Smedmyr B, T\u00f6tterman T, Eksborg S, Simonsson B (1989) Pharmacokinetic and metabolic studies of high-dose busulfan in adults. Eur J Clin Pharmacol 36: 525","journal-title":"Eur J Clin Pharmacol"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/BF00689702","volume":"28","author":"M Hassan","year":"1991","unstructured":"Hassan M, \u00d6berg G, Bekassy AN, Aschan J, Ehrsson H, Ljungman P, L\u00f6nnerholm G, Smedmyr B, Taube A, Wallin I, Simonsson B (1991) Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol 28: 130","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR9","first-page":"736","volume":"49","author":"RL Heidemann","year":"1989","unstructured":"Heidemann RL, Cole DE, Balis F, Sato J, Reaman GH, Packer RJ, Singler LJ, Ettinger LJ, Gillespie A, Sam J, Poplack DG (1989) Phase I and pharmacokinetic study of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res 49: 736","journal-title":"Cancer Res"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hep.1840040121","volume":"4","author":"GB Mac Donald","year":"1984","unstructured":"Mac Donald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED (1984) Veno-occlusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 4: 116","journal-title":"Hepatology"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","volume":"118","author":"GB Mac Donald","year":"1993","unstructured":"Mac Donald GB, Hinds MS, Fisher LD, Schoh HG, Wolford JL, Banaji M, Hardin BJ, Shulman HM, Clift RA (1993) Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 118: 255","journal-title":"Ann Intern Med"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1200\/JCO.1992.10.10.1569","volume":"10","author":"J Mansi","year":"1992","unstructured":"Mansi J, Costa F da, Viner C, Judson I, Gore M, Cunningham D (1992) High-dose busulfan in patients with myeloma. J Clin Oncol 10: 1569","journal-title":"J Clin Oncol"},{"key":"CR13","first-page":"135","volume":"10","author":"V M\u00e9resse","year":"1992","unstructured":"M\u00e9resse V, Hartmann O, Vassal G, Benhamou E, Valteau-Couanet D, Brugi\u00e8res L, Lemerle J (1992) Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant 10: 135","journal-title":"Bone Marrow Transplant"},{"key":"CR14","first-page":"3171","volume":"51","author":"PJ O'Dwyer","year":"1991","unstructured":"O'Dwyer PJ, La Creta F, Engstrom PF, Peter R, Tartagliaz L, Cole D, Litwin S, De Vito J, Poplack DG, De Lap RJ, Comis RL (1991) Phase I\/pharmacokinetic reevaluation of thiotepa. Cancer Res 51: 3171","journal-title":"Cancer Res"},{"key":"CR15","first-page":"6402","volume":"47","author":"WP Peters","year":"1987","unstructured":"Peters WP, Henner WD, Grochow L, Olsen G, Edwards S, Stanbuck H, Stuart A, Gockerman J, Moore J, Bast RC, Seigler HF, Colvin OM (1987) Clinical and pharmacologic effects of high-dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. Cancer Res 47: 6402","journal-title":"Cancer Res"},{"key":"CR16","first-page":"49","volume":"9","author":"V Ratanatharathon","year":"1992","unstructured":"Ratanatharathon V, Karanes C, Lum LG, Uberti J, Dan ME, Planque MM de, Schultz KR, Cronin S, Leisz MC, Mohamed A, Sensenbrenner LL (1992) Allogeneic bone marrow transplantation in high risk myeloid disorders using busulfan, cytosine arabinoside and cyclophosphamide (BAC). Bone Marrow Transplant 9: 49","journal-title":"Bone Marrow Transplant"},{"key":"CR17","first-page":"193","volume":"1","author":"PJ Shaw","year":"1986","unstructured":"Shaw PJ, Hugh-Jones K, Hobbs JR, Downie CDC, Barnes R (1986) Busulphan and cyclophosphamide cause little early toxicity during bone marrow transplantation in fifty children. Bone Marrow Transplant 1: 193","journal-title":"Bone Marrow Transplant"},{"key":"CR18","first-page":"539","volume":"21","author":"PJ Shaw","year":"1993","unstructured":"Shaw PJ, Earl JM, Stevens MM, Bergin ME, Burgess M, Dalla Pozza L, Kellie SJ (1993) Pharmacokinetics of busulphan with single daily dosing during BMT conditioning with busulphan\/cyclophosphamide (BUCY) for AML in children. Proc XXV SIOP Meet, in Med Pediatr Oncol 21: 539","journal-title":"Proc XXV SIOP Meet, in Med Pediatr Oncol"},{"key":"CR19","first-page":"192","volume":"10","author":"HM Shulman","year":"1992","unstructured":"Shulman HM, Hinterberger W (1992) Hepatic veno-occlusive disease ? liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 10: 192","journal-title":"Bone Marrow Transplant"},{"key":"CR20","first-page":"114","volume":"126","author":"HM Shulman","year":"1987","unstructured":"Shulman HM, Luk K, Deeg J, Shuman WB, Storb R (1987) Induction of hepatic veno-occlusive disease in dogs. Am J Pathol 126: 114","journal-title":"Am J Pathol"},{"key":"CR21","first-page":"94","volume":"49","author":"BA Teicher","year":"1988","unstructured":"Teicher BA, Holden SA, Cuchhi CA, Cathcart KNS, Karbut TT, Flatow JL, Frei E. III (1988) Combination ofN,N?,N?',-triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo. Cancer Res 49: 94","journal-title":"Cancer Res"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF00273524","volume":"23","author":"B Tranchand","year":"1989","unstructured":"Tranchand B, Ploin YD, Minuit MP, Spaet C, Biron P, Philip T, Ardiet C (1989) High-dose melphalan dosage adjustment: possibility of using a test-dose. Cancer Chemother Pharmacol 23: 95","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0378-4347(00)83928-6","volume":"428","author":"G Vassal","year":"1988","unstructured":"Vassal G, R\u00e9 M, Gouyette A (1988) Gas chromatographic-mass spectrometry assay for busulfan in biological fluids using a deuterated internal standard. J Chromatogr 428: 357","journal-title":"J Chromatogr"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/BF00257448","volume":"24","author":"G Vassal","year":"1989","unstructured":"Vassal G, Gouyette A, Hartmann O, Pico J-L, Lemerle J (1989) Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol 24: 386","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"881","DOI":"10.7326\/0003-4819-112-11-881_1","volume":"112","author":"G Vassal","year":"1990","unstructured":"Vassal G, Hartmann O, Benhamou E (1990) Busulfan and veno-occlusive disease of the liver. Ann Intern Med 112: 881","journal-title":"Ann Intern Med"},{"key":"CR26","first-page":"6203","volume":"50","author":"G Vassal","year":"1990","unstructured":"Vassal G, Deroussent A, Hartmann O, Challine D, Benhamou E, Valteau-Couanet D, Brugi\u00e8res L, Kalifa C, Gouyette A, Lemerle J (1990) Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 50: 6203","journal-title":"Cancer Res"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood.V79.9.2475.2475","volume":"79","author":"G Vassal","year":"1992","unstructured":"Vassal G, Deroussent A, Challine D, Hartmann O, Koscielny S, Valteau-Couanet D, Lemerle J, Gouyette A (1992) Is 600 mg\/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood 79: 2475","journal-title":"Blood"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1182\/blood.V82.3.1030.1030","volume":"82","author":"G Vassal","year":"1993","unstructured":"Vassal G, Fischer A, Challine D, Boland I, Ledheist F, Lemerle S, Vilmer E, Rahimy C, Souillet G, Gluckman E, Michel G, Deroussent A, Gouyette A (1993) Busulfan disposition below the age of three: alteration in children with lysosomal storage disease. Blood 82: 1030","journal-title":"Blood"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1182\/blood.V80.9.2425.2425","volume":"80","author":"AM Yeager","year":"1992","unstructured":"Yeager AM, Wagner JE, Graham ML, Jones RJ, Santos GW, Grochow LB (1992) Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. Blood 80: 2425","journal-title":"Blood"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00688324.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00688324\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00688324","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T10:59:33Z","timestamp":1585997973000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00688324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1995]]}},"alternative-id":["BF00688324"],"URL":"https:\/\/doi.org\/10.1007\/bf00688324","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995]]}}}